



Published on *SWOT Analysis* (<https://www.swotanalysis.info>)

Home > Global and China Alzheimer's Disease Therapeutics and Diagnostics Market Size, Status and Forecast 2020-2026

# Global and China Alzheimer's Disease Therapeutics and Diagnostics Market Size, Status and Forecast 2020-2026

**Publication ID:**

QYR11201664

**Publication Date:**

November 23, 2020

**Pages:**

98

**Publisher:**

QYR

**Region:**

Global [1]

**\$3,900.00**

Publication License Type \*

Single User License (PDF), \$3,900.00

Global License (PDF), \$7,800.00

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.

Add to cart



**Description:**

Global Alzheimer's Disease Therapeutics and Diagnostics Scope and Market Size

Alzheimer's Disease Therapeutics and Diagnostics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Alzheimer's Disease Therapeutics and Diagnostics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

Market segment by Type, the product can be split into

Biomarkers

Cholinesterase inhibitors

NMDA receptor antagonists

Brain imaging

Blood tests

Market segment by Application, split into

Drugs Market

Diagnostics Market

Based on regional and country-level analysis, the Alzheimer's Disease Therapeutics and Diagnostics market has been segmented as follows:

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Nordic

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia-Pacific

Latin America

Mexico

Brazil

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of Middle East & Africa

In the competitive analysis section of the report, leading as well as prominent players of the global Alzheimer's Disease Therapeutics and Diagnostics market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.

The key players covered in this study

Namenda

Aricept

Exelon

Solanezumab

Gantenerumab

Verubecestat

Pfizer

Eisai

Actavis

Lundbeck

Daiichi Sankyo

Novartis

TauRx

## **Table Of Contents:**

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Alzheimer's Disease Therapeutics and Diagnostics Market Size Growth Rate by Type: 2020 VS 2026

1.2.2 Biomarkers

1.2.3 Cholinesterase inhibitors

1.2.4 NMDA receptor antagonists

1.2.5 Brain imaging

1.2.6 Blood tests

1.3 Market by Application

1.3.1 Global Alzheimer's Disease Therapeutics and Diagnostics Market Share by Application: 2020 VS 2026

1.3.2 Drugs Market

- 1.3.3 Diagnostics Market
- 1.4 Study Objectives
- 1.5 Years Considered
- 2 Global Growth Trends
  - 2.1 Global Alzheimer's Disease Therapeutics and Diagnostics Market Perspective (2015-2026)
  - 2.2 Global Alzheimer's Disease Therapeutics and Diagnostics Growth Trends by Regions
    - 2.2.1 Alzheimer's Disease Therapeutics and Diagnostics Market Size by Regions: 2015 VS 2020 VS 2026
    - 2.2.2 Alzheimer's Disease Therapeutics and Diagnostics Historic Market Share by Regions (2015-2020)
    - 2.2.3 Alzheimer's Disease Therapeutics and Diagnostics Forecasted Market Size by Regions (2021-2026)
  - 2.3 Industry Trends and Growth Strategy
    - 2.3.1 Market Trends
    - 2.3.2 Market Drivers
    - 2.3.3 Market Challenges
    - 2.3.4 Market Restraints
- 3 Competition Landscape by Key Players
  - 3.1 Global Top Alzheimer's Disease Therapeutics and Diagnostics Players by Market Size
    - 3.1.1 Global Top Alzheimer's Disease Therapeutics and Diagnostics Players by Revenue (2015-2020)
    - 3.1.2 Global Alzheimer's Disease Therapeutics and Diagnostics Revenue Market Share by Players (2015-2020)
  - 3.2 Global Alzheimer's Disease Therapeutics and Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  - 3.3 Players Covered: Ranking by Alzheimer's Disease Therapeutics and Diagnostics Revenue
  - 3.4 Global Alzheimer's Disease Therapeutics and Diagnostics Market Concentration Ratio
    - 3.4.1 Global Alzheimer's Disease Therapeutics and Diagnostics Market Concentration Ratio (CR5 and HHI)
    - 3.4.2 Global Top 10 and Top 5 Companies by Alzheimer's Disease Therapeutics and Diagnostics Revenue in 2019
  - 3.5 Key Players Alzheimer's Disease Therapeutics and Diagnostics Area Served
  - 3.6 Key Players Alzheimer's Disease Therapeutics and Diagnostics Product Solution and Service
  - 3.7 Date of Enter into Alzheimer's Disease Therapeutics and Diagnostics Market
  - 3.8 Mergers & Acquisitions, Expansion Plans
- 4 Alzheimer's Disease Therapeutics and Diagnostics Breakdown Data by Type (2015-2026)
  - 4.1 Global Alzheimer's Disease Therapeutics and Diagnostics Historic Market Size by Type (2015-2020)
  - 4.2 Global Alzheimer's Disease Therapeutics and Diagnostics Forecasted Market Size by Type (2021-2026)

5 Alzheimer's Disease Therapeutics and Diagnostics Breakdown Data by Application (2015-2026)

5.1 Global Alzheimer's Disease Therapeutics and Diagnostics Historic Market Size by Application (2015-2020)

5.2 Global Alzheimer's Disease Therapeutics and Diagnostics Forecasted Market Size by Application (2021-2026)

6 North America

6.1 North America Alzheimer's Disease Therapeutics and Diagnostics Market Size (2015-2026)

6.2 North America Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2015-2020)

6.3 North America Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2015-2020)

6.4 North America Alzheimer's Disease Therapeutics and Diagnostics Market Size by Country (2015-2020)

6.4.1 United States

6.4.2 Canada

7 Europe

7.1 Europe Alzheimer's Disease Therapeutics and Diagnostics Market Size (2015-2026)

7.2 Europe Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2015-2020)

7.3 Europe Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2015-2020)

7.4 Europe Alzheimer's Disease Therapeutics and Diagnostics Market Size by Country (2015-2020)

7.4.1 Germany

7.4.2 France

7.4.3 U.K.

7.4.4 Italy

7.4.5 Russia

7.4.6 Nordic

7.4.7 Rest of Europe

8 China

8.1 China Alzheimer's Disease Therapeutics and Diagnostics Market Size (2015-2026)

8.2 China Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2015-2020)

8.3 China Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2015-2020)

8.4 China Alzheimer's Disease Therapeutics and Diagnostics Market Size by Region (2015-2020)

8.4.1 China

8.4.2 Japan

8.4.3 South Korea

8.4.4 Southeast Asia

8.4.5 India

8.4.6 Australia

#### 8.4.7 Rest of Asia-Pacific

### 9 Japan

9.1 Japan Alzheimer's Disease Therapeutics and Diagnostics Market Size (2015-2026)

9.2 Japan Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2015-2020)

9.3 Japan Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2015-2020)

9.4 Japan Alzheimer's Disease Therapeutics and Diagnostics Market Size by Country (2015-2020)

9.4.1 Mexico

9.4.2 Brazil

### 10 Southeast Asia

10.1 Southeast Asia Alzheimer's Disease Therapeutics and Diagnostics Market Size (2015-2026)

10.2 Southeast Asia Alzheimer's Disease Therapeutics and Diagnostics Market Size by Type (2015-2020)

10.3 Southeast Asia Alzheimer's Disease Therapeutics and Diagnostics Market Size by Application (2015-2020)

10.4 Southeast Asia Alzheimer's Disease Therapeutics and Diagnostics Market Size by Country (2015-2020)

10.4.1 Turkey

10.4.2 Saudi Arabia

10.4.3 UAE

10.4.4 Rest of Middle East & Africa

### 11 Key Players Profiles

#### 11.1 Namenda

11.1.1 Namenda Company Details

11.1.2 Namenda Business Overview

11.1.3 Namenda Alzheimer's Disease Therapeutics and Diagnostics Introduction

11.1.4 Namenda Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2015-2020)

11.1.5 Namenda Recent Development

#### 11.2 Aricept

11.2.1 Aricept Company Details

11.2.2 Aricept Business Overview

11.2.3 Aricept Alzheimer's Disease Therapeutics and Diagnostics Introduction

11.2.4 Aricept Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2015-2020)

11.2.5 Aricept Recent Development

#### 11.3 Exelon

11.3.1 Exelon Company Details

11.3.2 Exelon Business Overview

11.3.3 Exelon Alzheimer's Disease Therapeutics and Diagnostics Introduction

11.3.4 Exelon Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2015-2020)

- 11.3.5 Exelon Recent Development
- 11.4 Solanezumab
  - 11.4.1 Solanezumab Company Details
  - 11.4.2 Solanezumab Business Overview
  - 11.4.3 Solanezumab Alzheimer's Disease Therapeutics and Diagnostics Introduction
  - 11.4.4 Solanezumab Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2015-2020)
  - 11.4.5 Solanezumab Recent Development
- 11.5 Gantenerumab
  - 11.5.1 Gantenerumab Company Details
  - 11.5.2 Gantenerumab Business Overview
  - 11.5.3 Gantenerumab Alzheimer's Disease Therapeutics and Diagnostics Introduction
  - 11.5.4 Gantenerumab Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2015-2020)
  - 11.5.5 Gantenerumab Recent Development
- 11.6 Verubecestat
  - 11.6.1 Verubecestat Company Details
  - 11.6.2 Verubecestat Business Overview
  - 11.6.3 Verubecestat Alzheimer's Disease Therapeutics and Diagnostics Introduction
  - 11.6.4 Verubecestat Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2015-2020)
  - 11.6.5 Verubecestat Recent Development
- 11.7 Pfizer
  - 11.7.1 Pfizer Company Details
  - 11.7.2 Pfizer Business Overview
  - 11.7.3 Pfizer Alzheimer's Disease Therapeutics and Diagnostics Introduction
  - 11.7.4 Pfizer Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2015-2020)
  - 11.7.5 Pfizer Recent Development
- 11.8 Eisai
  - 11.8.1 Eisai Company Details
  - 11.8.2 Eisai Business Overview
  - 11.8.3 Eisai Alzheimer's Disease Therapeutics and Diagnostics Introduction
  - 11.8.4 Eisai Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2015-2020)
  - 11.8.5 Eisai Recent Development
- 11.9 Actavis
  - 11.9.1 Actavis Company Details
  - 11.9.2 Actavis Business Overview
  - 11.9.3 Actavis Alzheimer's Disease Therapeutics and Diagnostics Introduction
  - 11.9.4 Actavis Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2015-2020)
  - 11.9.5 Actavis Recent Development

## 11.10 Lundbeck

11.10.1 Lundbeck Company Details

11.10.2 Lundbeck Business Overview

11.10.3 Lundbeck Alzheimer's Disease Therapeutics and Diagnostics Introduction

11.10.4 Lundbeck Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2015-2020)

11.10.5 Lundbeck Recent Development

## 11.11 Daiichi Sankyo

10.11.1 Daiichi Sankyo Company Details

10.11.2 Daiichi Sankyo Business Overview

10.11.3 Daiichi Sankyo Alzheimer's Disease Therapeutics and Diagnostics Introduction

10.11.4 Daiichi Sankyo Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2015-2020)

10.11.5 Daiichi Sankyo Recent Development

## 11.12 Novartis

10.12.1 Novartis Company Details

10.12.2 Novartis Business Overview

10.12.3 Novartis Alzheimer's Disease Therapeutics and Diagnostics Introduction

10.12.4 Novartis Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2015-2020)

10.12.5 Novartis Recent Development

## 11.13 TauRx

10.13.1 TauRx Company Details

10.13.2 TauRx Business Overview

10.13.3 TauRx Alzheimer's Disease Therapeutics and Diagnostics Introduction

10.13.4 TauRx Revenue in Alzheimer's Disease Therapeutics and Diagnostics Business (2015-2020)

10.13.5 TauRx Recent Development

## 12 Analyst's Viewpoints/Conclusions

## 13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

### **Companies Mentioned:**

Namenda

Aricept

Exelon

Solanezumab

Gantenerumab  
Verubecestat  
Pfizer  
Eisai  
Actavis  
Lundbeck  
Daiichi Sankyo  
Novartis  
TauRx

### **License Types:**

#### **Single User License (PDF)**

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

#### **Site License (PDF)\***

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

## Global License (PDF)\*

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

\*If Applicable.

No. 1101, Golden Square, 3rd Floor,  
24th Main, J P Nagar, 1st Phase,  
Bangalore, Karnataka, India- 560078

India: +91-8762746600

info@domain.com

-->

## NAVIGATE

[About Us](#)

[Reports by Region](#)

[FAQ](#)

[Privacy Policy](#)

[TERMS & CONDITIONS](#)

[CONTACT](#)

## RECENT POSTS

[What is SWOT Analysis?](#)

March 12

[How to use market research to bring your idea to life?](#)

March 11

[How to gain business insights using syndicated market research?](#)

March 10

---

Source URL:<https://www.swotanalysis.info/qyr/global-and-china-alzheimers-disease-therapeutics-and-diagnostics-market-size-status-and-forecast>

Links

[1] <https://www.swotanalysis.info/region/global>